Nanoliposome of Linolenic acid for Methicillin-resistant Staphylococcus aureus treatment

Methicillin-resistant Staphylococcus aureus (MRSA) presents a major threat to a broad range of healthcare and community associated infections. MRSA bacteria have rapidly developed resistance to multiple drugs throughout the antibiotic history. It is imperative to develop novel antimicrobial strategies to address the currently shrinking therapeutic options against MRSA. Herein, we developed a nanoliposome formulation of natural antimicrobial compound such as linolenic acid and evaluate its potential application for the treatment of MRSA infection as well as its safety. We found that Nano-liposomal linolenic acid (LipoLNA) was successfully synthesized. LipoLNA was able to inhibit MRSA growth and exhibited a good safety profile on normal mammalian cells.